Small New Jersey firm pushes further into sterile injectables


New Jersey-based Teligent, a small specialty generic pharmaceutical company, will expand its manufacturing facility, giving it the capacity to quadruple its production.

The company will spend about $50 million to add 110,000 of space to its facility in the Atlantic City area. Peter Gallagher, Teligent’s vice president of strategic affairs, told the the press of Atlantic City, that the company expects the project to be complete next year, allowing it to double employment to about 200 people by 2018.  

Teligent will expand packaging and production, including adding a  sterile injectable manufacturing suite. The company last fall bought Canada-based Alveda Pharmaceuticals for $35.4 million, moving into the sterile injectables market in Canada.  

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Teligent reported 2015 revenues of $44.3 million.

- read the press of Atlantic City story

Related Articles: 
Pfizer building modular biologics plant in China
UPDATED: Pfizer closing Hospira plant in Colorado, 100 jobs to be lost

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.